Evidence map›Paper›PMID 40667416›Full record

ArticleFuture pharmacology2025

Safety Toxicology Study of Reassortant Mopeia-Lassa Vaccine in Guinea Pigs.

Bradley S Wahle, Peter Pushko, Katie Albanese, Dylan M Johnson, Irina Tretyakova, Igor S Lukashevich, Thomas Rudge

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bradley S WahleMRIGlobal, Kansas City, MO 64110, USA.
Peter PushkoMedigen, Inc., Frederick, MD 21701, USA.ORCID 0000-0002-1073-6981
Katie AlbaneseBattelle, West Jefferson, OH 43162, USA.
Dylan M JohnsonSandia National Laboratory, Department of Biotechnology & Bioengineering, Livermore, CA 94550, USA.ORCID 0000-0002-3630-0588
Irina TretyakovaMedigen, Inc., Frederick, MD 21701, USA.
Igor S LukashevichDepartment of Pharmacology and Toxicology, Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville, KY 40292, USA.ORCID 0000-0001-6523-5116
Thomas RudgeBattelle, West Jefferson, OH 43162, USA.ORCID 0000-0002-8801-8744

Funding

NIAID NIH HHS HHSN272201800013C
6 · The paper itself

Abstract

Background: (1)Mopeia-Lassa reassortant ML29 virus is an investigational, reassortant virus vaccine for the prevention of Lassa fever caused by Lassa virus (LASV). Methods: (2)The vaccine virus ML29-SF was prepared in Vero cells using a serum-free culture medium under Good Manufacturing Practice. A 2-week repeat dose toxicity study was performed in guinea pigs under Good Laboratory Practice (GLP) regulations to assess the local and systemic toxicological effects. Results: (3)Following an intramuscular (IM) or subcutaneous (SC) injection of 10 Conclusions: (4)Overall, this single-dose vaccine was locally and systemically well tolerated even after a two-dose repeat administration, confirming the high level of safety of ML29-SF vaccination and supporting the future evaluation of this LASV vaccine, including in clinical trials.

Indexed as

GLPLassareassortanttoxicologyvaccinevirus

Identifiers

PMID40667416
PMCPMC12263097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.